Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
LifeStance Health Group, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $229.4 million, net income $46.7 million. Guidance initiated.
- Period
- the fourth quarter and full year ended December 31, 2022
- Revenue
- $229.4 million
- Net income
- $46.7 million
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
December 31, 2022. (All results compared to prior-year comparative period, unless otherwise noted) 2022 Highlights and 2023 Outlook • Fourth quarter revenue increased 21% to $229.4 million and full year revenue of $859.5 million increased $192.0 million or 29% compared to revenue of $667.5 million • Clinician base increased 18% to 5,631 clinicians, including 200
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
LifeStance Health Group, Inc.: Amended bylaws to update advance notice provisions for universal proxy rules, conform to DGCL, and make administrative changes (effective 2023-03-06).
- Change
- bylaw amendment
- Effective
- 2023-03-06
Exact text from the filing
On March 6, 2023, the Board of Directors (the “Board”) of the Company approved Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately, with such amendments including updates to the advance notice provisions to address the adoption by the Securities and Exchange Commission (the “SEC”) of “universal proxy” rules and other updates to conform with the Delaware General Corporation Law (the “DGCL”) regarding notice of adjourned stockholder meetings and stockholder list requirements.
View on SEC.gov